Altimmune

Altimmune is a therapeutics, treatment, and vaccine development company that looks to find response and prevention solutions. The company was founded by De-chu Christopher Tang in 1997, in Gaithersburg, Maryland, United States.

The company is known for their programs that deal with peptide-based therapeutics for liver diseases, peptide-conjugated immuno-stimulants for cancer, and intranasal vaccines for Anthrax and Influenza.

With the outbreak of COVID-19, Altimmune announced the development of a single-dose, intranasal vaccine against the virus which was caused by the SARS-CoV-2 virus. The vaccine design and synthesis has been advanced to animal testing and manufacturing. A Phase 2 clinical study with NasoVAX demonstrated the ability the delivery system was durable and stimulated a broad immune response against the influenza virus. They believe the same delivery system would work for the vaccine in development for COVID-19.